微血管密度与血管内皮生长因子受体-3在骨髓增生异常综合征患者中的表达及意义

目的检测骨髓增生异常综合征患者骨髓中微血管密度和血管内皮生长因子受体-3表达水平并探讨其临床意义。方法采用免疫组织化学染色检测54例骨髓增生异常综合症患者、20例非恶性血液病患者对照组骨髓组织中微血管密度和血管内皮生长因子受体-3表达水平,采用蛋白质印迹法检测上述研究对象骨髓单个核细胞中血管内皮生长因子受体-3蛋白表达水平,分析其与临床特征的相关性。结果骨髓增生异常综合症患者骨髓组织中微血管密度和血管内皮生长因子受体-3表达水平明显高于非恶性血液病对照组,差异具有统计学意义(P0.05),而骨髓增生异常综合症低危组、中危组及高危组中微血管密度与血管内皮生长因子受体-3的表达水平无显著差异(P0.05),经相关性分析微血管密度和血管内皮生长因子受体-3在骨髓增生异常综合症患者骨髓中表达呈正相关关系。结论骨髓增生异常综合症患者骨髓存在明显血管新生及血管内皮生长因子受体-3高表达,其表达水平可能参与骨髓增生异常综合症发病、发展等过程,并可能影响骨髓增生异常综合症预后,通过检测微血管密度和血管内皮生长因子受体-3的表达可为临床抗脉管新生方法治疗骨髓增生异常综合症提供实验依据。

MICROVESSEL DENSITY AND EXPRESSION OF VEGFR-3 IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ITS SIGNIFICANCE

Objective: To investigate the level of MVD and exoression level of VEGFR-3 in the patients with MDS, and to explore the clinical significance. Methods: The pathologic specimens of the myeloid tissues were collected from 54 patients with MDS and 20 patients with non-hematologic malignancies, and were processed for routine paraffin embedding. The levels of MVD and the expression of VEGFR-3 were determined by the method of IHC and Western blotting. The correlations between MVD and VEGFR-3, and with clinic characteristics were analyzed. Results: The levels of MVD and VEGFR-3 in the patients with MDS were much higher than those in control group (P < 0.05). A positive correlation between MVD and VEGFR-3 in the patients with MDS was found. Conclusion: Angiogenesis and high expression of VEGFR-3 were founded in the MDS patients. VEGFR-3 may participate in the occurrence progress and prognosis of MDS. Determining the MVD and the expression of VEGFR-3 may provide experimental evidence for anti-angiogenic therapy.